The CaSR inhibitor NPS-2390 increased the urinary citrate concentration and reduced crystal deposition in the rat nephrolithiasis model compared with group B. Therefore, we speculated that NPS-2390 might be a potential drug for the treatment of nephrolithiasis, especially when exposed to ethylene glycol, but the effect must be further verified by animal experiments and clinical trials before introducing it in clinical practice. This evidence concerns the gene CASR and nephrolithiasis.